In Corporate News

Vero Beach, FL April 14, 2016 – Nascent Biotech, Inc. (“Nascent Biotech, Inc.” or “the Company”) (OTC.NBIO), announced today that Doug Karas, Vice President of Performance Analysis & Investment Risk at Franklin Templeton Investments, has joined its Board of Directors.

Mr. Karas is a Certified Public Accountant and has extensive accounting, auditing, finance and consulting experience. He will lend similar guidance while serving on Nascent Biotech’s BOD.

Nascent CEO, Sean Carrick, enthusiastically welcomed Mr. Karas and stated that “Mr. Karas will add to the leadership and direction of the Company as we move forward toward our goal of the Company being listed on an exchange at a future date.”


About Nascent Biotech, Inc.:

Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information, please visit our website:

Safe Harbor:

Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10-K, filed on May 2, 2015, and subsequent and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact Information:


Nascent Biotech, Inc.

Sean Carrick

President | CEO

601 21st Street Suite 300
Vero Beach, FL 32960


Recent Posts
Nascent Biotech logoNascent Biotech logo